CICigna
Is the price fair?
Neither cheap nor expensive: nothing decisive, though cheap vs its sector.
In its normal range: P/E 12.7 vs a 12.8 median over 30 quarters (−1% vs median).
Sector median 25.1× across 135 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What CI's price assumes
Cigna trades at 12.7× earnings against 25.7× for the median Healthcare Plans name, cheaper than its own group.
Trailing P/E · Healthcare Plans median 25.7 · cheaper than the typical name in its group
- Price / sales
- 0.29
Price / sales · today's price, trailing year to Jun 30, 2026
- Price / book
- 1.90
Price / book · today's price, trailing year to Jun 30, 2026
- EV / sales
- 0.38
EV / sales
Details›
- Price / booktoday's price, trailing year to Jun 30, 2026
- 1.90
- EV / EBITtoday's price, trailing year to Jun 30, 2026
- 10.7
- EV / salestoday's price, trailing year to Jun 30, 2026
- 0.38
- Healthcare median P/E503 names
- 27.9
- Healthcare Plans median P/E11 names
- 25.7
- Market capitalisation264.2 million shares, counted Jul 24, 2026
- $81.1B
| Method | Per share |
|---|---|
| Its own P/E history, lower quartile | $279.33 |
| Its own P/E history, median | $309.01 |
| Its own P/E history, upper quartile | $363.74 |
| 52-week range | $240.32 – $315.83 |
| Today | $306.89 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Against its own past
Its multiples now against their own history, and how much of the price move came from earnings rather than the multiple.
Healthcare
Ranks #29 of 436 by RyuScore